Neoadjuvant chemotherapy with ifosfamide and cisplatin combination in advanced head and neck cancer: a retrospective analysis of 519 patients: a single institution experience
| Autor: | P. M. Parikh, A. Bakshi, K. A. Pathak, V. R. Pai, C. Deshmukh, Deepak M. Parikh, Rajesh C. Mistry, A. T. Mazumdar |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty Adolescent medicine.medical_treatment India Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Ifosfamide Single institution Antineoplastic Agents Alkylating Aged Response rate (survey) Cisplatin Chemotherapy Hematology business.industry Head and neck cancer Carcinoma General Medicine Middle Aged medicine.disease Neoadjuvant Therapy Squamous carcinoma Treatment Outcome Head and Neck Neoplasms Female business medicine.drug |
| Zdroj: | Medical oncology (Northwood, London, England). 20(1) |
| ISSN: | 1357-0560 |
| Popis: | Advanced head and neck cancer is a major therapeutic problem in India. Ifosfamide has shown significant activity as a single agent in head and neck squamous carcinoma. In this study, we present our experience with two cycles of ifosfamide and cisplatin in the neoadjuvant setting given to a total of 519 patients. The complete response rate was 20% and the overall response rate was 80%. The treatment was well tolerated, there was no need for dose reduction, and there were no life-threatening side effects. We feel that this high response rate is sufficient to warrant more studies using ifosfamide-based combinations in a neoadjuvant setting for squamous carcinoma of the head and neck. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink